FINANCIAL DISCLOSURE STATEMENT
Authors of manuscripts submitted for publication consideration that involve drug or drug-related products must
advise the editor-in-chief in writing of any financial interest—including, but not limited to, consulting or
speaking fees, honoraria, grants, and royalty fees, including those received from intermediaries (eg,
communication companies, advertising agencies)—associated with the manufacturer of the drug. The editor-inchief
will decide on the necessity and form of disclosure in articles published in the journal.
COPYRIGHT AGREEMENT
Copyright forms, transferring copyright ownership to Formulary, are required to be signed by all article authors
(a separate form for each author/coauthor of a single manuscript, each showing an original signature, is required).
The copyright form must not include any written notations other than the items requested on the form (printed
name, signature, address, Social Security number for manuscripts with an honorarium attached, etc.). The
original copyright form should be mailed (not emailed or faxed) to Formulary when the article is submitted for
publication consideration. Copyright forms can be obtained from the editorial office or via the journal’s web site
at www.formularyjournal.com (under the “Editorial Resources” then “Information for Authors” section of the
site, accessible on the bottom part of the directory located in the left-hand column on the home page).
SUGGESTED ARTICLE TOPICS
Formulary is accepting short, tightly focused articles (see article text under manuscript preparation for details) on
the following topics:
Disease state management reviews with a focus on pharmacotherapeutic options.
Drug class reviews.
Successful strategies to contain costs of specific drugs or drug classes.
Process-oriented articles that describe how to maintain an effective formulary system.
Commentaries on how the structure and role of formulary committees are changing, especially
with regard to expansion of “traditional” responsibilities.
Head-to-head comparative studies of drugs.
Consolidation of multiple formularies and formulary management responsibilities in an integrated
healthcare system.
Drug use evaluations.
Outcomes research.
Pharmacoeconomic evaluations of drugs.
Policy formulation and implementation regarding drug therapy issues and compliance with
formulary committee guidelines, JCAHO guidelines, or other regulatory agency guidelines.
Continuous quality improvement, total quality management, and quality assurance issues in
formulary management.
Use of electronic information systems to streamline drug data collection and analyses and drug
management activities.
Update articles on newer drugs/biologics (possibly including soon-to-be-approved drugs) or new
drug combinations for a selected disease state or therapeutic area.
Update articles on newer uses of already approved drugs (including expanded indications and
robust evidence-based off-label uses [ie, not based on case reports]).
Update articles on the use of drugs in important subpopulations for which the evidence strongly
supports such uses.
Legal issues related to drug management/formulary development.
Institution-based original articles. These may include successful drug cost containment strategies
developed and implemented at your organization, drug management/intervention programs,
clinical disease management guidelines that your organization has developed, successful
therapeutic interchange programs, process- and results-oriented articles that describe how your
organization addressed a controversial or difficult drug-related issue, and other topics related to
drug and drug management issues. May also include other original research, review articles, and
commentaries of interest to physicians, pharmacists, and other members of formulary committees
at hospitals and managed-care settings.
Drug and drug class reviews should contain pertinent information related to formulary
considerations, including a comparison of relevant data related to clinical effectiveness and
efficacy, side effect profiles, and regimens. Comparative drug studies should include numbers of
study participants, specific drug-associated results, and the statistical significance of those results
(ie, P values and confidence intervals). Additional data to consider are specific results related to
morbidity and mortality and quality of life measures. Especially valuable pharmacoeconomics
studies are those that evaluate the impact of a drug on the overall healthcare costs to the hospital or
managed care organization.
Articles with a disease state guideline or a critical care pathway should have recommendations for
first- and second-line pharmaceutical agents and discuss the rationale for those recommendations.
OTHER ACCEPTED SUBMISSIONS
Articles from drug therapy-related bulletins and newsletters may also be submitted for publication consideration
following receipt of appropriate permissions. Letters to the editor are also invited. Acknowledgment of receipt of
such communications shall be made only if accepted for publication.
MANUSCRIPT PREPARATION
In general, Formulary follows the editorial style detailed in the American Medical Association Manual of Style.
Manuscripts should be prepared as follows:
Title page. Include only the title and subtitle of the paper.
Author page. List only those individuals who substantially contributed to the preparation of the
paper. For each author, include name, highest academic degree(s), and institutional affiliations. If
the article was written while an author was at a different facility, include that affiliation. Names of
persons to be acknowledged also should be provided. At the bottom of the page, list the
corresponding author with full mailing address as well as telephone and fax numbers, and email
address.
Abstract. A 100- to 150-word abstract summarizing the salient points of the article should be
submitted with the manuscript. This should include the rationale, a brief description of methods,
key results, and conclusion. Do not cite references in the abstract.
Article text. Articles should be 2,500 to 5,000 words, including references, figures, and tables.
Clearly identify headlines and subheads. Tables and figures should be prepared on separate pages
at the end of the manuscript. Ideally, the number of references should not exceed 30-40. See below
for specific information on how to submit manuscripts and what documents must be included;
initial submission by email is encouraged (tstultz@advanstar.com).
Tables. We encourage authors to develop tables. Types of tables to consider include those
comparing clinical trials, drug characteristics, doses and regimens, guidelines for therapeutic uses,
pharmacoeconomics outcome data, and new drugs in development for a particular disease. Each
table should be numbered and called out in the text. Tables should have titles. List all
abbreviations, notes, and references at the bottom of each table.
Figures. Figures should be of good quality for reproduction, preferably submitted as a glossy,
black-and-white or color print. Captions are needed for all figures. Write the number of each figure
and the caption with a soft-tipped indelible marker on the back of the illustration or photograph.
Permissions. Authors are responsible for securing any necessary permission to publish a figure or
table. Copies of the permissions must be included when manuscripts are submitted.
Abbreviations. All abbreviations should be written out initially and followed with the abbreviation
in parentheses. Periods should not be used with any abbreviations (AMA style).
Drug nomenclature. Refer to drugs by their nonproprietary names. Proprietary names of FDAapproved
drugs should be given (in parentheses) at their first mention, along with the
manufacturer, if available. Pricing information should be included whenever possible.
REFERENCES
Adequate documentation is required. References should be sequentially numbered in the text and listed at the end
of the article in numerical sequence. Authors are requested to limit the number of references to 30-40, as
mentioned previously.
In references, list all author names up to a total of four. If there are more than four, list three followed by et al.
Journal abbreviations should be the same as those used in Index Medicus and International Pharmaceutical
Abstracts.
Style references as follows:
Journal Reference
1. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: Hemodynamic effects and tolerability. Circulation
1995;91:691-7.
Textbook Reference
1. Risby ED, Risch SC, Stoudemire A. Mood Disorders. In: Stoudemire A, ed. Clinical Psychiatry for Medical
Students. 2nd ed. Philadelphia:JP Lippincott Co; 1994;169-232.
Agency Reference
1. Global Strategy for Asthma Management and Prevention, NHLBI/WHO Workshop Report. Global Initiative for
Asthma. Bethesda, MD: National Institutes of Health; 1995 US Department of Health and Human Services Publication
95-3659.
MANUSCRIPT SUBMISSION
One copy of the manuscript should be submitted to the editorial office electronically (tstultz@advanstar.com). A
second copy of the manuscript (including tables, figures, and references) should be sent by regular mail.
IMPORTANT: The mailed manuscript must be accompanied by a signed cover letter that includes the name,
address, phone, fax, and email address of the corresponding author and a financial disclosure statement. The
letter must also include a statement indicating that the manuscript has not been accepted for publication and is
not under consideration for publication by any other journal.
IMPORTANT: The mailed hard copy of the manuscript should contain the signed copyright release form(s).
Acceptability of submitted papers will be determined by the clinical editor and staff editors following review by
three peer-reviewers. Publication decisions will normally be communicated to the corresponding author generally
within 60 days of receipt of the manuscript.
Material will be edited as necessary. Galley proofs will be sent to the corresponding author for correction and
approval prior to publication.
Revised article submission. Manuscripts accepted and revised per comments from reviewers should be submitted
electronically (tstultz@advanstar.com).
Reprints. All authors will receive two complimentary copies of the issue in which their article is published.
Additional reprints can be obtained by calling 440-891-3155.
Honoraria. Formulary generally pays an honorarium for each published article, to help defray the cost of
manuscript preparation.
CHECKLIST FOR ARTICLE SUBMISSION
___ Signed cover letter with financial interest disclaimer, statement of exclusive submission, and copyright form.
___ One email copy and one mailed copy of the manuscript.
___ Title page, author page.
___ Abstract.
___ Article text, references, tables/figures with captions/charts.
___ Permissions to reproduce any previously published material.
ADDRESS SUBMISSIONS TO:
Formulary
Advanstar Communications
Attn, Tara Stultz
7500 Old Oak Blvd
Cleveland, OH 44130
Phone: 440-891-2689
Fax: 440-891-2683
Email: tstultz@advanstar.com
刊名字顺( Alphabetical List of Journals):
返回页首 